NCT00089765View on ClinicalTrials.gov

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 10, 2004

Study Completion Date

August 15, 2007

Conditions
Von Hippel-Lindau Syndrome
Interventions
DRUG

Ranibizumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT00089765 - Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | Biotech Hunter | Biotech Hunter